AstraZeneca, the UK’s second-most valuable company, is in advanced talks with US pharmaceutical giant Bristol Myers Squibb over a potential $400 billion merger, according to multiple reports published on Sunday. The proposed deal would create one of the world’s largest pharmaceutical companies by market value, with the combined entity valued at approximately £300 billion based on current figures. Both companies have declined to comment on the reports, which cite sources familiar with the discussions.
AstraZeneca’s shares fell 7% in early trading on Monday, reflecting investor concerns over the potential deal. The company’s London-listed shares were down 6.2% by mid-morning, contributing to a largely flat FTSE 100 index. The Financial Times first reported the discussions, stating that while progress has been made, the deal may be delayed or fall apart. The talks have been ongoing for several months, according to the report.
Regulatory and market scrutiny expected
If finalized, the merger would face significant regulatory hurdles, given the heightened scrutiny of large pharmaceutical deals by antitrust authorities. Analysts note that the combined company would be scrutinized by competition watchdogs in both the US and UK, particularly under the current administration’s push for domestic investment. The Trump administration’s antitrust authorities have previously intervened in major mergers, including in the pharmaceutical sector.
AstraZeneca, headquartered in Cambridge, has been expanding its presence in the US market under Chief Executive Pascal Soriot. In July, the company completed an additional listing on the New York Stock Exchange, allowing American investors to buy its shares directly while maintaining its London listing. Soriot has previously stated that AstraZeneca does not need mergers and acquisitions to meet its 2030 revenue targets, though the company has not ruled out strategic deals.
The proposed merger would create a company with a combined market value exceeding $400 billion, combining AstraZeneca’s £196 billion valuation with Bristol Myers Squibb’s £133 billion valuation. Bristol Myers Squibb, listed in New York, specializes in cardiovascular and oncology treatments, while AstraZeneca has a broader portfolio including respiratory and rare disease drugs.
Historical context and industry implications
The potential deal evokes memories of Pfizer’s failed attempt to acquire AstraZeneca in 2014, which collapsed amid political and regulatory resistance. At the time, then-Labour leader Ed Miliband criticized Pfizer’s assurances about protecting research and jobs as unreliable. The proposed merger also follows a trend of British firms either relocating their primary listings abroad or being acquired by foreign companies, raising questions about London’s ability to retain its most valuable corporations.
AstraZeneca has insisted it remains committed to its UK headquarters and London Stock Exchange listing, despite its growing US focus. In September 2020, the company struck a $50 billion deal with the Trump administration to invest in US manufacturing and research facilities. Soriot has described AstraZeneca as a "very American company" in the past, though the firm continues to operate from its Cambridge base.
Market reaction and analyst perspectives
Analysts have mixed views on the potential merger. Some argue it could strengthen AstraZeneca’s position in the US market, where Bristol Myers Squibb has a strong presence in oncology. Others caution that regulatory challenges and integration risks could outweigh the benefits. Chris Beauchamp, chief market analyst at IG, noted that companies often signal one stance publicly while pursuing deals privately, stating: "Companies saying one thing and doing another is a well-trodden path."
The deal’s progress remains uncertain, with sources indicating that while discussions are serious, they are not guaranteed to result in an agreement. Both companies have yet to provide official confirmation or denial of the reports.